Modelling the lifetime cost-effectiveness of catheter ablation for atrial fibrillation with heart failure

Gao, Lan and Moodie, Marj 2019, Modelling the lifetime cost-effectiveness of catheter ablation for atrial fibrillation with heart failure, BMJ Open, vol. 9, no. 9, pp. 1-9, doi: 10.1136/bmjopen-2019-031033.

Attached Files
Name Description MIMEType Size Downloads

Title Modelling the lifetime cost-effectiveness of catheter ablation for atrial fibrillation with heart failure
Author(s) Gao, LanORCID iD for Gao, Lan
Moodie, MarjORCID iD for Moodie, Marj
Journal name BMJ Open
Volume number 9
Issue number 9
Start page 1
End page 9
Total pages 9
Publisher BMJ Publishing Group Ltd
Place of publication London, Eng.
Publication date 2019-09-05
ISSN 2044-6055
Keyword(s) atrial fibrillation
catheter ablation
cost-effectiveness analysis
heart failure
medical therapy
Summary Objectives: Assessing the cost-effectiveness credentials of this intervention in patients with concomitant atrial fibrillation (AF) and heart failure (HF) compared with usual medical therapy. Design: A Markov model comprising two health states (ie, alive or dead) was constructed. The transition probabilities were directly derived from published Kaplan-Meier curves of the pivotal randomised controlled trial and extrapolated over the cohort's lifetime using recommended methods. Costs of catheter ablation, outpatient consultations, hospitalisation, medications and examinations were included. Resource use and unit costs were sourced from government websites or published literature. A lifetime horizon and a healthcare system perspective were taken. All costs and benefits were discounted at 3% annually. Deterministic (DSA) and probabilistic sensitivity analyses (PSA) were run around the key model parameters to test the robustness of the base case results. Participants: A hypothetical Australian cohort of patients with concomitant AF and HF who are resistant to antiarrhythmic treatment. Interventions: Catheter ablation versus medical therapy. Results: The catheter ablation was associated with a cost of $A44 377 per person, in comparison to $A28 506 for the medical therapy alone over a lifetime. Catheter ablation contributed to 4.58 quality-adjusted life years (QALYs) and 6.99 LY gains compared with 4.30 QALYs and 6.53 LY gains, respectively, in the medical therapy arm. The incremental cost-effectiveness ratio was $A55 942/QALY or $A35 020/LY. The DSA showed that results were highly sensitive to costs of ablation and time horizon. The PSA yielded very consistent results with the base case. Conclusions: Offering catheter ablation procedure to patients with systematic paroxysmal or persistent AF who failed to respond to antiarrhythmic drugs was associated with higher costs, greater benefits. When compared with medical therapy alone, this intervention is not cost-effective from an Australia healthcare system perspective.
Language eng
DOI 10.1136/bmjopen-2019-031033
Indigenous content off
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2019, Author(s) (or their employer(s))
Free to Read? Yes
Persistent URL

Document type: Journal Article
Collections: Faculty of Health
School of Health and Social Development
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 20 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Mon, 16 Sep 2019, 13:29:45 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact